In 50–60% of cases, systemic anaplastic large cell lymphoma (ALCL) is characterized by the t(2;5)(p23;q35) or one of its variants, considered to be causative for anaplastic lymphoma kinase (ALK)-positive (ALK+) ALCL. Key pathogenic events in ALK-negative (ALK−) ALCL are less well defined. We have previously shown that deregulation of oncogenic genes surrounding the chromosomal breakpoints on 2p and 5q is a unifying feature of both ALK+ and ALK− ALCL and predisposes for occurrence of t(2;5). Here, we report that the invariant chain of the MHC-II complex CD74 or li, which is encoded on 5q32, can act as signaling molecule, and whose expression in lymphoid cells is usually restricted to B cells, is aberrantly expressed in T cell-derived ALCL. Accordingly, ALCL shows an altered DNA methylation pattern of the CD74 locus compared to benign T cells. Functionally, CD74 ligation induces cell death of ALCL cells. Furthermore, CD74 engagement enhances the cytotoxic effects of conventional chemotherapeutics in ALCL cell lines, as well as the action of the ALK-inhibitor crizotinib in ALK+ ALCL or of CD95 death-receptor signaling in ALK− ALCL. Additionally, a subset of ALCL cases expresses the proto-oncogene MET, which can form signaling complexes together with CD74. Finally, we demonstrate that the CD74-targeting antibody-drug conjugate STRO-001 efficiently and specifically kills CD74-positive ALCL cell lines in vitro. Taken together, these findings enabled us to demonstrate aberrant CD74-expression in ALCL cells, which might serve as tool for the development of new treatment strategies for this lymphoma entity.
Background/Objectives: Burkitt lymphoma (BL) is an aggressive germinal center B-cell (gcBC) malignancy driven by MYC deregulation and cooperating molecular alterations. A mouse model combining constitutive MYC and PI3K activity in gcBC closely recapitulates key features of human BL, but its epigenetic similarity to the human disease has not been investigated in detail. Here, we compared genome-wide DNA methylation patterns between human sporadic EBV-negative BL and this murine model. Methods: DNA methylation profiles of 37 human BL samples and 20 gcBC controls were compared with those of 8 murine tumors from the MYC/PI3K driven mouse model and 11 murine gcBC controls using Illumina methylation arrays. Differentially methylated CpGs were identified using linear modeling, and chromatin-state enrichment, cross-species gene overlap, protein interaction, and pathway enrichment analyses were performed. Results: BL showed global DNA hypomethylation in both species and distinct methylation profiles from gcBCs. CpGs hypomethylated in BL were enriched at enhancers, whereas hypermethylated CpGs were strongly enriched at poised promoters. We identified 695 genes with shared hypermethylation and 512 with shared hypomethylation between human and murine BL. Restricting the analysis to regulatory regions identified 86 genes consistently hypomethylated in both species. These genes were significantly enriched for regulation of intracellular signal transduction and sphingolipid signaling. Included are regulators of GTPase and kinase signaling, such as GNA13, RASA3, RASAL1, SPRED2, PIK3R2, PRKCA, PRKCE, and FYN. The conserved set also contained genes with established roles in germinal center B-cell biology, including FOXO1, BACH2, and NR3C1. Conclusions: Human and murine BL share conserved regulatory DNA methylation features, supporting the MYC/PI3K mouse model as a system to study epigenetic mechanisms of BL.